Revolution Medicines Says Rasonque Improved Survival Across Patient Subgroups
The company said the recently approved pancreatic cancer drug improved overall survival in previously treated patients, regardless of RAS mutation status.
The company said the recently approved pancreatic cancer drug improved overall survival in previously treated patients, regardless of RAS mutation status.